Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dihydrofolate reductase (DHFR) in Plasmodium species, including Plasmodium falciparum and Plasmodium vivax, is a critical enzyme involved in the folate pathway, essential for nucleotide biosynthesis and DNA replication. In these parasites, DHFR is part of a bifunctional enzyme complex with thymidylate synthase (TS), known as DHFR-TS. It catalyzes the NADPH-dependent reduction of dihydrofolate (DHF) to tetrahydrofolate (THF), which is necessary for the synthesis of purines, thymidylate, and certain amino acids. Plasmodial DHFR is targeted by antifolate drugs such as pyrimethamine and cycloguanil. Resistance arises from specific point mutations that alter inhibitor binding.
Inhibition of dihydrofolate reductase
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dihydrofolate Reductase (Plasmodium) (DHFR).